{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:41:21Z","timestamp":1770795681556,"version":"3.50.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cytogfr.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:02:28Z","timestamp":1764230548000},"page":"2-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inflammation and Type 1 interferon signaling in pancreatic adenocarcinoma: Insights into inflammasome driven crosstalk and therapeutic advances"],"prefix":"10.1016","volume":"87","author":[{"given":"Spyridoula D.","family":"Katsarou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Panagopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-1156","authenticated-orcid":false,"given":"Stavroula","family":"Baritaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2025.11.006_bib1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting Cancer Incidence and Deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1258538","article-title":"An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1625114","article-title":"The role of inflammatory factors in the tumor microenvironment of pancreatic cancer","volume":"16","author":"Yuan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib6","article-title":"The interplay between inflammation and stromal components in pancreatic cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2013.07.014","article-title":"Inflammatory cytokines in human pancreatic cancer","volume":"345","author":"Roshani","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1323198","article-title":"Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma","volume":"15","author":"Joseph","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.816517","article-title":"Modulation of Type I interferon responses to influence tumor-immune cross talk in PDAC","volume":"10","author":"Cattolico","year":"2022","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.821816","article-title":"Role of hypoxia in the interferon response","volume":"13","author":"Arnaiz","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/biomedicines13010203","article-title":"Conventional Chemotherapy and Inflammation: what Is the Role of the Inflammasome in the Tumor Microenvironment?","volume":"13","author":"Colarusso","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41420-023-01783-6","article-title":"Mechanisms and effects of NLRP3 in digestive cancers","volume":"10","author":"Si","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41420-023-01550-7","article-title":"The trigger for pancreatic disease: NLRP3 inflammasome","volume":"9","author":"Liu","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100889","article-title":"The NLRP3 inflammasome: mechanism of action, role in disease and therapies","volume":"76","author":"Wang","year":"2020","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib17","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.3892\/mmr.2016.5196","article-title":"Critical role of oncogenic KRAS in pancreatic cancer (Review)","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib18","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1053\/j.gastro.2013.01.071","article-title":"Roles for KRAS in pancreatic tumor development and progression","volume":"144","author":"Di Magliano","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2017.01.002","article-title":"The cornerstone K-RAS mutation in pancreatic adenocarcinoma: from cell signaling network, target genes, biological processes to therapeutic targeting","volume":"111","author":"Jonckheere","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib21","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.3390\/cancers13215481","article-title":"Oncogenic KRAS-induced feedback inflammatory signaling in pancreatic cancer: an overview and new therapeutic opportunities","volume":"13","author":"Bansod","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-024-01528-7","article-title":"Targeting inflammation as cancer therapy","volume":"17","author":"Wang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib23","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1172\/JCI91561","article-title":"NF-\u03baB regulates GDF-15 to suppress macrophage surveillance during early tumor development","volume":"127","author":"Ratnam","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/ijms20030676","article-title":"Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity","volume":"20","author":"Padoan","year":"2019","journal-title":"IJMS"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-cancerbio-061421-035400","article-title":"Cancer-associated fibroblasts: lessons from pancreatic cancer","volume":"7","author":"Sherman","year":"2023","journal-title":"Annu Rev. Cancer Biol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib28","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Gr\u00fcnwald","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","article-title":"Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy","volume":"19","author":"Zheng","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929005","article-title":"Double-edged effects of interferons on the regulation of cancer-immunity cycle","volume":"10","author":"Zhang","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103204","article-title":"Type I interferons in pancreatic cancer and development of new therapeutic approaches","volume":"159","author":"Blaauboer","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib32","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/0008-5472.CAN-21-1677","article-title":"MYC- and MIZ1-dependent vesicular transport of double-strand RNA controls immune evasion in pancreatic ductal adenocarcinoma","volume":"81","author":"Krenz","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat8657","article-title":"cGAS in action: expanding roles in immunity and inflammation","volume":"363","author":"Ablasser","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.781032","article-title":"The function of cGAS-STING pathway in treatment of pancreatic cancer","volume":"12","author":"Mohseni","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib35","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","article-title":"Repression of the Type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma","volume":"10","author":"Muthalagu","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.558341","article-title":"SOCS proteins participate in the regulation of innate immune response caused by viruses","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41392-025-02307-7","article-title":"Phosphorylated Toll-like receptor 3 nuclear translocation in cancer cell promotes metastasis and chemoresistance","volume":"10","author":"Wang","year":"2025","journal-title":"Sig Transduct. Target Ther."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s44321-025-00214-6","article-title":"PARP7 as a new target for activating anti-tumor immunity in cancer","volume":"17","author":"Popova","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","article-title":"Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors","volume":"76","author":"Baird","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122857","article-title":"Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer","volume":"3","author":"Kinkead","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib42","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fimmu.2017.01132","article-title":"Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development","volume":"8","author":"Kantono","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/03936155221096690","article-title":"Prognostic association between NLRP3 inflammasome expression level and operable pancreatic adenocarcinoma","volume":"37","author":"Zheng","year":"2022","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-023-01407-7","article-title":"Involvement of inflammasomes in tumor microenvironment and tumor therapies","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1466440","article-title":"The role of AIM2 in inflammation and tumors","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13046-025-03366-y","article-title":"Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential","volume":"44","author":"Singh","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40364-022-00391-3","article-title":"The role of pyroptosis in modulating the tumor immune microenvironment","volume":"10","author":"Wu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661323","article-title":"Tumor NLRP3-Derived IL-1b Drives the IL-6\/STAT3 axis resulting in sustained MDSC-mediated immunosuppression","volume":"12","author":"Tengesdal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20172222","article-title":"Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity","volume":"215","author":"Boucher","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib50","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fimmu.2017.00873","article-title":"The role of interferons in inflammation and inflammasome activation","volume":"8","author":"Kopitar-Jerala","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.2829","article-title":"The PYRIN domain\u2013only protein POP3 inhibits ALR inflammasomes and regulates responses to infection with DNA viruses","volume":"15","author":"Khare","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12964-023-01466-w","article-title":"cGAS-STING, inflammasomes and pyroptosis: an overview of crosstalk mechanism of activation and regulation","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3389\/fimmu.2020.00615","article-title":"Research advances in how the cGAS-STING pathway controls the cellular inflammatory response","volume":"11","author":"Wan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib55","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1158\/2767-9764.CRC-23-0065","article-title":"Pancreatic ductal adenocarcinoma cells regulate NLRP3 activation to generate a tolerogenic microenvironment","volume":"3","author":"Amo-Aparicio","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib56","doi-asserted-by":"crossref","first-page":"858","DOI":"10.21037\/tlcr-22-311","article-title":"NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma","volume":"11","author":"Gu","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107079","article-title":"New insights into nucleic acid sensor AIM2: The potential benefit in targeted therapy for cancer","volume":"200","author":"Cui","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib58","article-title":"The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome","volume":"15","author":"Liang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pharmthera.2019.05.012","article-title":"Cellular determinants and therapeutic implications of inflammation in pancreatic cancer","volume":"201","author":"Stone","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1408312","article-title":"Unveiling the role of interleukin-6 in pancreatic cancer occurrence and progression","volume":"15","author":"Song","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib61","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1158\/1535-7163.MCT-21-0083","article-title":"Targeting tumor\u2013stromal IL6\/STAT3 signaling through IL1 receptor inhibition in pancreatic cancer","volume":"20","author":"Dosch","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cytogfr.2025.11.006_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1291106","article-title":"JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer","volume":"6","author":"Lu","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054105","article-title":"STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer","volume":"11","author":"Da","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cytogfr.2025.11.006_bib64","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1158\/2767-9764.CRC-23-0189","article-title":"NLRP3 inflammasome activation expands the immunosuppressive myeloid stroma and antagonizes the therapeutic benefit of STING activation in glioblastoma","volume":"5","author":"Lea","year":"2025","journal-title":"Cancer Res. Commun."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:45:38Z","timestamp":1769604338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":64,"alternative-id":["S1359610125001509"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.11.006","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation and Type 1 interferon signaling in pancreatic adenocarcinoma: Insights into inflammasome driven crosstalk and therapeutic advances","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}